About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker MGNX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 30, 2026A Study of MGC030 in Participants With Advanced Solid Tumors
NCT07822399 · Urothelial Cancer, GastroEsophageal Cancer
MGC030
MGNX
MacroGenics
Phase 1Recruiting
was not yet recruiting
314Sep 2028Registry ↗
Oct 28, 2026A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 · Advanced Solid Tumor, Advanced Cancer
MGC026 Dose Escalation, MGC026 Dose for Expansion
MGNX
MacroGenics
Phase 1Recruiting394Oct 2028Registry ↗
Jul 28, 2026A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773 · Leukemia, Acute Myeloid, Myelodysplastic Syndromes
MGD024
MGNX
MacroGenics
Phase 1Active, not recruiting130Nov 2026Registry ↗
Jun 2, 2026A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347 · Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallo…
Lorigerlimab
MGNX
MacroGenics
Phase 2Recruiting80Jul 2027Registry ↗
May 22, 2026A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castratio…
NCT05848011 · Androgen-Independent Prostatic Cancer, Androgen-Independent…
lorigerlimab, docetaxel
MGNX
MacroGenics
Phase 2Completed154Feb 19, 2026Registry ↗
Apr 27, 2026A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236 · Advanced Solid Tumors, NSCLC Adenocarcinoma
MGC028
MGNX
MacroGenics
Phase 1Recruiting124Nov 2026Registry ↗
Feb 9, 2026A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate…
NCT05551117 · Castration-Resistant Prostatic Cancer, Androgen-Independent…
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duoc…
MGNX
MacroGenics
Phase 2Terminated192Jul 4, 2024Registry ↗
Oct 14, 2025A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496 · Advanced Solid Tumor, Castration-Resistant Prostatic Cancer
vobramitamab duocarmazine, lorigerlimab
MGNX
MacroGenics
Phase 1Completed31Jun 24, 2025Registry ↗
Aug 11, 2025Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Ca…
NCT02475213 · Melanoma, Head and Neck Cancer
Enoblituzumab Schedule 1, Pembrolizumab
MGNX
MacroGenics
Phase 1Completed146Aug 18, 2021Registry ↗
Jul 31, 2025MGC018 With or Without MGA012 in Advanced Solid Tumors
NCT03729596 · Squamous Cell Carcinoma of Head and Neck, Triple Negative B…
vobramitamab duocarmazine
MGNX
MacroGenics
Phase 1/2Terminated143Mar 18, 2023Registry ↗
Jun 8, 2025Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gast…
NCT04082364 · Gastric Cancer, Gastroesophageal Junction Cancer
margetuximab, Retifanlimab
MGNX
MacroGenics
Phase 2/3Completed82Jan 15, 2024Registry ↗
Mar 28, 2025A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
NCT05261191 · Human Immunodeficiency Virus I Infection, Immunodeficiency…
MGD020, MGD014
MGNX
MacroGenics
Phase 1Completed17May 29, 2024Registry ↗
Mar 17, 2025Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesopha…
NCT02689284 · Gastric Cancer, Stomach Cancer
Margetuximab 10 mg/kg, Margetuximab 15 mg
MGNX
MacroGenics
Phase 1/2Completed95Jan 2021Registry ↗
Mar 17, 2025Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastati…
NCT02492711 · HER-2 Positive Breast Cancer, Metastatic Neoplasm
Margetuximab, Trastuzumab
MGNX
MacroGenics
Phase 3Completed624Aug 11, 2021Registry ↗
Mar 13, 2025Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refract…
NCT01828021 · Breast Cancer
Margetuximab
MGNX
MacroGenics
Phase 2Completed25Dec 7, 2016Registry ↗
Mar 6, 2025MGD019 DART® Protein in Unresectable/Metastatic Cancer
NCT03761017 · Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer M…
Lorigerlimab
MGNX
MacroGenics
Phase 1Completed162Aug 29, 2024Registry ↗
Feb 26, 2025Safety Study of MGAH22 in HER2-positive Carcinomas
NCT01148849 · Breast Cancer, Gastric Cancer
margetuximab
MGNX
MacroGenics
Phase 1Completed66Jun 14, 2022Registry ↗
Jan 30, 2024Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
NCT02152956 · AML
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetu…
MGNX
MacroGenics
Phase 1/2Terminated244Jul 5, 2022Registry ↗
Dec 21, 2023A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
NCT03219268 · Advanced Solid Tumors, Hematologic Neoplasms
tebotelimab 1 mg, tebotelimab 3 mg
MGNX
MacroGenics
Phase 1Completed277Feb 8, 2023Registry ↗
Dec 20, 2023Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
NCT04634825 · Head and Neck Cancer, Head and Neck Neoplasms
Enoblituzumab, Retifanlimab
MGNX
MacroGenics
Phase 2Terminated62Jul 29, 2022Registry ↗
Dec 20, 2023Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onse…
NCT00920582 · Type 1 Diabetes Mellitus
Teplizumab Herold Regimen, Placebo
MGNX
MacroGenics
Phase 3Terminated254Apr 2012Registry ↗
Dec 5, 2023The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabet…
NCT00385697 · Type 1 Diabetes Mellitus
Teplizumab, Placebo
MGNX
MacroGenics
Phase 2/3Completed554Jun 2010Registry ↗
Nov 3, 2023Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
NCT00625586 · Pancreatic Cancer
RAV12, Gemcitabine
MGNX
MacroGenics
Phase 2Terminated2Jan 21, 2009Registry ↗
Aug 9, 2023Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (C…
NCT00870818 · Type 1 Diabetes Mellitus
Blood samples for safety, Patient reported outcome question…
MGNX
MacroGenics
Not applicableTerminated219Feb 2011Registry ↗
Sep 2, 2022MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
NCT03570918 · HIV-1-infection
MGD014
MGNX
MacroGenics
Phase 1Completed21Sep 28, 2021Registry ↗
May 31, 2022Flotetuzumab Expanded Access Program
NCT04678466 · Acute Myeloid Leukemia, AML
flotetuzumab
MGNX
MacroGenics
—No longer available——Registry ↗
May 19, 2022MGD009/MGA012 Combination in Relapsed/Refractory Cancer
NCT03406949 · Advanced Solid Tumors
obrindatamab, retifanlimab
MGNX
MacroGenics
Phase 1Completed25Apr 27, 2022Registry ↗
Feb 22, 2022Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected Wes…
NCT01206504 · West Nile Virus Infection
MGAWN1
MGNX
MacroGenics
—No longer available——Registry ↗
Feb 22, 2022A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
NCT00515385 · West Nile Virus
MGAWN1, MGAWN1
MGNX
MacroGenics
Phase 1Completed40Dec 2008Registry ↗
Feb 22, 2022RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
NCT00101972 · Cancer
monoclonal antibody RAV12
MGNX
MacroGenics
Phase 1Completed53May 2008Registry ↗
Feb 10, 2022Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Sever…
NCT00954915 · Psoriasis
teplizumab
MGNX
MacroGenics
Phase 1/2Terminated1Jul 2010Registry ↗
Feb 10, 2022Treatment of West Nile Virus With MGAWN1
NCT00927953 · West Nile Neuroinvasive Disease, West Nile Virus Infection
MGAWN1, Placebo - normal saline
MGNX
MacroGenics
Phase 2Terminated13Feb 2011Registry ↗
Feb 8, 2022Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
NCT04129320 · Head and Neck Cancer, Squamous Cell Carcinoma of Head and N…
enoblituzumab, MGA012
MGNX
MacroGenics
Phase 2/3Withdrawn0Oct 2020Registry ↗
Feb 8, 2022MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
NCT03531632 · Colorectal Cancer Metastatic
MGD007 + MGA012
MGNX
MacroGenics
Phase 1/2Completed38Feb 8, 2020Registry ↗
Feb 8, 2022Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
NCT02982941 · Neuroblastoma, Rhabdomyosarcoma
Enoblituzumab
MGNX
MacroGenics
Phase 1Completed25May 22, 2019Registry ↗
Feb 8, 2022Safety Study of MGD009 in B7-H3-expressing Tumors
NCT02628535 · Mesothelioma, Bladder Cancer
MGD009
MGNX
MacroGenics
Phase 1Terminated67Nov 25, 2019Registry ↗
Feb 8, 2022Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
NCT02381314 · Melanoma, Non Small Cell Lung Cancer
enoblituzumab plus ipilimumab
MGNX
MacroGenics
Phase 1Completed24Nov 9, 2017Registry ↗
Feb 8, 2022Phase 1 Study of MGD010 in Healthy Subjects
NCT02376036 · Healthy Subjects
MGD010, Placebo
MGNX
MacroGenics
Phase 1Completed73Feb 2017Registry ↗
Feb 8, 2022Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
NCT02248805 · Colorectal Carcinoma
MGD007
MGNX
MacroGenics
Phase 1Completed95Jul 2, 2018Registry ↗
Feb 8, 2022Tissue Procurement Substudy for Participants in Study CP-MGA271-01
NCT01918930 · Melanoma
MGA271
MGNX
MacroGenics
Phase 1Terminated6Oct 2016Registry ↗
Feb 8, 2022Safety Study of MGA271 in Refractory Cancer
NCT01391143 · Prostate Cancer, Melanoma
MGA271
MGNX
MacroGenics
Phase 1Completed179Apr 18, 2019Registry ↗
Feb 8, 2022Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
NCT01189422 · Type 1 Diabetes Mellitus
teplizumab or placebo
MGNX
MacroGenics
Phase 1Terminated1Feb 2011Registry ↗

42 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:00 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances